Baxter International BAX BioPharma Solutions — Net Sales
Discontinued — last reported Q1 '23
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Baxter International’s 10-Q, filed April 27, 2023, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's biopharma solutions — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's biopharma solutions — net sales?
- Baxter International (BAX) reported biopharma solutions — net sales of $139M in Q1 2023.
- How has Baxter International's biopharma solutions — net sales changed year-over-year?
- Baxter International's biopharma solutions — net sales decreased by 10.9% year-over-year, from $156M to $139M.
- What does biopharma solutions — net sales mean?
- This metric represents the total revenue generated from the BioPharma Solutions segment, which provides specialized contract manufacturing and development services for pharmaceutical and biotechnology companies. It reflects the company's ability to monetize its technical expertise in sterile fill-finish, formulation, and packaging for complex drug products. This segment is a key indicator of the company's role as a strategic partner in the drug development supply chain.